Oncolytic specificity of newcastle disease virus is mediated by selectivity for apoptosis-resistant cells

Journal of Virology

Volumn 85, Issue 12, 2011, Pages 6015-6023

  Mansour, Mena ^a,b   Palese, Peter ^a,b   Zamarin, Dmitriy ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Mount Sinai School of Microbiology   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; INTERFERON; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUS; PACLITAXEL; PROTEIN BCL XL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON TYPE I; LUNG NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

NEWCASTLE DISEASE VIRUS; RNA VIRUSES;

EID: 79958119977     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01537-10     Document Type: Article

References (51)

1. Altomonte, J., S. Marozin, R. M. Schmid, and O. Ebert. 2010. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 18:275-284.
2. Besch, R., et al. 2009. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119:2399-2411.
3. Borden, E. C., et al. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6:975-990.
4. Chau, B. N., C. W. Pan, and J. Y. Wang. 2006. Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domain. PLoS One 1:e82.
5. Chawla-Sarkar, M., D. W. Leaman, and E. C. Borden. 2001. Preferentialinduction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 7:1821-1831.
6. Datta, R., et al. 1995. Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 6:363-370.
7. Ebert, O., et al. 2004. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64:3265-3270.
8. Elankumaran, S., D. Rockemann, and S. K. Samal. 2006. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 80:7522-7534.
9. Elmore, S. 2007. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35:495-516.
10. Everett, H., and G. McFadden. 1999. Apoptosis: an innate immune response to virus infection. Trends Microbiol. 7:160-165.
11. Everett, H., and G. McFadden. 2001. Viruses and apoptosis: meddling with mitochondria. Virology 288:1-7.
12. Fernandez-Sesma, A., et al. 2006. Influenza virus evades innate and adaptive immunity via the NS1 protein. J. Virol. 80:6295-6304.
13. Fiola, C., et al. 2006. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int. J. Cancer 119:328-338.
14. Freeman, A. I., et al. 2006. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228.
15. Hay, S., and G. Kannourakis. 2002. A time to kill: viral manipulation of the cell death program. J. Gen. Virol. 83:1547-1564.
16. Hotte, S. J., et al. 2007. An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 13:977-985.
17. Ito, Y., et al. 1992. Fusion regulation proteins on the cell surface: isolation and characterization of monoclonal antibodies which enhance giant polykaryocyte formation in Newcastle disease virus-infected cell lines of human origin. J. Virol. 66:5999-6007.
18. Kumar, S., L. Gao, B. Yeagy, and T. Reid. 2008. Virus combinations and chemotherapy for the treatment of human cancers. Curr. Opin. Mol. Ther. 10:371-379.
19. Lam, K. M., A. C. Vasconcelos, and A. A. Bickford. 1995. Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Microb. Pathog. 19:169-174.
20. Lazar, I., et al. 2010. The oncolytic activity of Newcastle disease virus NDVHUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J. Virol. 84: 639-646.
21. Lorence, R. M., et al. 2007. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7:157-167.
22. Minn, A. J., C. M. Rudin, L. H. Boise, and C. B. Thompson. 1995. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910.
23. Nuessler, V., et al. 1999. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 13:1864-1872.
24. Park, M. S., A. Garcia-Sastre, J. F. Cros, C. F. Basler, and P. Palese. 2003. Newcastle disease virus V protein is a determinant of host range restriction. J. Virol. 77:9522-9532.
25. Park, M. S., et al. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J. Virol. 77:1501-1511.
26. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.
27. Prince, A. M., and H. S. Ginsberg. 1957. Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. I. Characteristics of the virus-cell interaction. J. Immunol. 79:94-106.
28. Puhlmann, J., F. Puehler, D. Mumberg, P. Boukamp, and R. Beier. 2010. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 29:2205-2216.
29. Quinlivan, M., et al. 2005. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 79:8431-8439.
30. Randall, R. E., and S. Goodbourn. 2008. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89:1-47.
31. Ravindra, P. V., et al. 2009. Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res. 144:350-354.
32. Reichard, K. W., et al. 1992. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52:448-453.
33. Roulston, A., R. C. Marcellus, and P. E. Branton. 1999. Viruses and apoptosis. Annu. Rev. Microbiol. 53:577-628.
34. Schulze, T., et al. 2009. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58:61-69.
35. Shin, E. J., et al. 2007. Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol. Head Neck Surg. 136:811-817.
36. Sinkovics, J. G., and J. C. Horvath. 2000. Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol. 16:1-15.
37. Smyth, M. J. 2005. Type I interferon and cancer immunoediting. Nat. Immunol. 6:646-648.
38. Stojdl, D. F., et al. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825.
39. Vigil, A., O. Martinez, M. A. Chua, and A. Garcia-Sastre. 2008. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol. Ther. 16:1883-1890.
40. Vigil, A., et al. 2007. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67:8285-8292.
41. Vucic, D., H. R. Stennicke, M. T. Pisabarro, G. S. Salvesen, and V. M. Dixit. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10:1359-1366.
42. Washburn, B., and V. Schirrmacher. 2002. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int. J. Oncol. 21:85-93.
43. Watanabe, J., et al. 2004. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135:604-612.
44. Wong, J., et al. 2010. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. J. Gastrointest. Surg. 14:7-14.
45. Yaacov, B., et al. 2008. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 15:795-807.
46. Youle, R. J., and A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9:47-59.
47. Yuan, B., R. Latek, M. Hossbach, T. Tuschl, and F. Lewitter. 2004. siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res. 32:W130-W134.
48. Zamarin, D., A. Garcia-Sastre, X. Xiao, R. Wang, and P. Palese. 2005. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog. 1:e4.
49. Zamarin, D., et al. 2009. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol. Ther. 17:697-706.
50. Zamarin, D., A. Vigil, K. Kelly, A. Garcia-Sastre, and Y. Fong. 2009. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 16:796-804.
51. Zhirnov, O. P., T. E. Konakova, T. Wolff, and H. D. Klenk. 2002. NS1 protein of influenza A virus down-regulates apoptosis. J. Virol. 76:1617-1625.